These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: Long-term Results After 7 Years of a Randomized Clinical Trial. Witzke O; Nitschke M; Bartels M; Wolters H; Wolf G; Reinke P; Hauser IA; Alshuth U; Kliem V Transplantation; 2018 May; 102(5):876-882. PubMed ID: 29166336 [TBL] [Abstract][Full Text] [Related]
23. Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus Disease. Halleck F; Khadzhynov D; Schrezenmeier E; Lehner L; Budde K; Staeck O Transplant Proc; 2017 Dec; 49(10):2280-2284. PubMed ID: 29198661 [TBL] [Abstract][Full Text] [Related]
24. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients. Ahsan N; Holman MJ; Yang HC Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699 [TBL] [Abstract][Full Text] [Related]
25. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients? Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344 [TBL] [Abstract][Full Text] [Related]
26. Comparison of standard versus low-dose valganciclovir regimens for cytomegalovirus prophylaxis in high-risk liver transplant recipients. Bixby AL; Fitzgerald L; Park JM; Kaul D; Tischer S Transpl Infect Dis; 2021 Oct; 23(5):e13713. PubMed ID: 34428337 [TBL] [Abstract][Full Text] [Related]
27. Cytomegalovirus Immunoglobulin After Thoracic Transplantation: An Overview. Grossi P; Mohacsi P; Szabolcs Z; Potena L Transplantation; 2016 Mar; 100 Suppl 3(Suppl 3):S1-4. PubMed ID: 26900989 [TBL] [Abstract][Full Text] [Related]
28. The efficacy and safety of valganciclovir vs. oral ganciclovir in the prevention of symptomatic CMV infection in children after solid organ transplantation. Lapidus-Krol E; Shapiro R; Amir J; Davidovits M; Steinberg R; Mor E; Avitzur Y Pediatr Transplant; 2010 Sep; 14(6):753-60. PubMed ID: 20477976 [TBL] [Abstract][Full Text] [Related]
29. Comparison of Preemptive Therapy and Antiviral Prophylaxis for Prevention of Cytomegalovirus in Seropositive Liver Transplant Recipients. Liu AW; Jutivorakool K; Fisher CE; Rakita RM; Reyes JD; Bhattacharya RB; Jerome KR; Limaye AP Transplantation; 2018 Apr; 102(4):632-639. PubMed ID: 29215460 [TBL] [Abstract][Full Text] [Related]
30. Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients. Fayek SA; Mantipisitkul W; Rasetto F; Munivenkatappa R; Barth RN; Philosophe B HPB (Oxford); 2010 Dec; 12(10):657-63. PubMed ID: 21083790 [TBL] [Abstract][Full Text] [Related]
31. Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients. McKeen JT; Tsapepas DS; Li H; Anamisis A; Martin ST Prog Transplant; 2015 Mar; 25(1):39-44. PubMed ID: 25758799 [TBL] [Abstract][Full Text] [Related]
32. Selective low-dose valganciclovir for prevention of cytomegalovirus disease following kidney transplantation. Avidan YP; Paul M; Rahamimov R; Bishara J; Samra Z; Edna S; Mor E J Infect; 2008 Sep; 57(3):236-40. PubMed ID: 18674820 [TBL] [Abstract][Full Text] [Related]
33. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients. Boillat Blanco N; Pascual M; Venetz JP; Nseir G; Meylan PR; Manuel O Transplantation; 2011 Jan; 91(2):251-5. PubMed ID: 21099744 [TBL] [Abstract][Full Text] [Related]